Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval
Executive Summary
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.
You may also be interested in...
Safety Concerns Prevented EU Approval For GSK’s Jesduvroq In Non-Dialysis CKD Patients
The European Medicines Agency recommended against the approval of GSK’s Jesduvroq in patients with CKD-related anemia who are not on dialysis because of concerns around its safety profile in these patients.
GSK Pulls EU Filing For Jesduvroq In CKD Anemia After Label Narrowed
GSK’s Jesduvroq was set for imminent EU approval to treat anemia in patients with chronic kidney disease receiving dialysis, but the firm has withdrawn its marketing authorization application after the EMA recommended excluding non-dialysis patients from the label.
Lilly Unlucky? Lilly Leads Big Pharma In US FDA Complete Response Letters
Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab – the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.